NFATc1 marks articular cartilage progenitors and negatively determines articular chondrocyte differentiation

  1. Fan Zhang
  2. Yuanyuan Wang
  3. Ying Zhao
  4. Manqi Wang
  5. Bin Zhao
  6. Bin Zhou
  7. Xianpeng Ge  Is a corresponding author
  1. Xuan Wu Hospital of the Capital Medical University, China
  2. Central South University, China
  3. Albert Einstein College of Medicine, United States
  4. Chinese Academy of Sciences, China

Abstract

The origin and differentiation mechanism of articular chondrocytes remain poorly understood. Broadly, the difference in developmental mechanisms of articular and growth-plate cartilage is still less elucidated. Here, we identified that the nuclear factor of activated T-cells cytoplasmic 1 (NFATc1) is a crucial regulator of articular, but not growth-plate, chondrocyte differentiation during development. At the early stage of mouse knee development (embryonic day 13.5), NFATc1-expressing cells were mainly located in the flanking region of the joint interzone. With development, NFATc1-expressing cells generated almost all articular chondrocytes, but not chondrocytes in limb growth-plate primordium. NFATc1-expressing cells displayed prominent capacities for colony formation and multipotent differentiation. Transcriptome analyses revealed a set of characteristic genes in NFATc1-enriched articular cartilage progenitors. Strikingly, the expression of NFATc1 was diminished with articular chondrocyte differentiation and suppressing NFATc1 expression in articular cartilage progenitors was sufficient to induce spontaneous chondrogenesis while overexpressing NFATc1 suppresses chondrogenesis. Mechanistically, NFATc1 negatively regulated the transcriptional activity of the Col2a1 gene. Thus, our results reveal that NFATc1 characterizes articular, but not growth-plate, cartilage progenitors during development and negatively determines articular chondrocyte differentiation at least partly through regulating COL2A1 gene transcription.

Data availability

All data generated or analyzed during this study are included in the manuscript and supporting file. The raw datasets of RNA-seq are available in Dryad Digital Repository (doi:10.5061/dryad.2fqz612rw).

The following data sets were generated

Article and author information

Author details

  1. Fan Zhang

    Xuan Wu Hospital of the Capital Medical University, Beijing, China
    Competing interests
    The authors declare that no competing interests exist.
  2. Yuanyuan Wang

    Xuan Wu Hospital of the Capital Medical University, Beijing, China
    Competing interests
    The authors declare that no competing interests exist.
  3. Ying Zhao

    Xuan Wu Hospital of the Capital Medical University, Beijing, China
    Competing interests
    The authors declare that no competing interests exist.
  4. Manqi Wang

    Central South University, Changsha, China
    Competing interests
    The authors declare that no competing interests exist.
  5. Bin Zhao

    Department of Genetics, Albert Einstein College of Medicine, New York, United States
    Competing interests
    The authors declare that no competing interests exist.
  6. Bin Zhou

    Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, Shanghai, China
    Competing interests
    The authors declare that no competing interests exist.
  7. Xianpeng Ge

    Xuan Wu Hospital of the Capital Medical University, Beijing, China
    For correspondence
    xianpeng.ge@xwhosp.org
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-1291-2096

Funding

National Natural Science Foundation of China (81100767)

  • Xianpeng Ge

Beijing Natural Science Foundation (5222008)

  • Xianpeng Ge

Natural Science Foundation of Capital Medical University (1220010146)

  • Xianpeng Ge

Outstanding Young Researcher Award of Beijing Municipality (N/A)

  • Xianpeng Ge

Outstanding Researcher Award of Xuanwu Hospital Capital Medical University (N/A)

  • Xianpeng Ge

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Ethics

Animal experimentation: All animal studies followed the recommendations in the Guide for the Care and Use of Laboratory Animals of the U.S. National Institutes of Health and were approved by Institutional Animal Care and Use Committee at Capital Medical University (protocol #: AEEI-2022-036).

Reviewing Editor

  1. Di Chen, Chinese Academy of Sciences, China

Publication history

  1. Preprint posted: June 29, 2022 (view preprint)
  2. Received: July 3, 2022
  3. Accepted: February 12, 2023
  4. Accepted Manuscript published: February 15, 2023 (version 1)

Copyright

© 2023, Zhang et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 249
    Page views
  • 87
    Downloads
  • 0
    Citations

Article citation count generated by polling the highest count across the following sources: Crossref, PubMed Central, Scopus.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Fan Zhang
  2. Yuanyuan Wang
  3. Ying Zhao
  4. Manqi Wang
  5. Bin Zhao
  6. Bin Zhou
  7. Xianpeng Ge
(2023)
NFATc1 marks articular cartilage progenitors and negatively determines articular chondrocyte differentiation
eLife 12:e81569.
https://doi.org/10.7554/eLife.81569

Further reading

    1. Genetics and Genomics
    2. Medicine
    Joshua K Park, Shantanu Bafna ... Ron Do
    Research Article

    Background: Causality between plasma triglyceride (TG) levels and atherosclerotic cardiovascular disease (ASCVD) risk remains controversial despite more than four decades of study and two recent landmark trials, STRENGTH and REDUCE-IT. Further unclear is the association between TG levels and non-atherosclerotic diseases across organ systems.

    Methods: Here, we conducted a phenome-wide, two-sample Mendelian randomization (MR) analysis using inverse-variance weighted (IVW) regression to systematically infer the causal effects of plasma TG levels on 2,600 disease traits in the European ancestry population of UK Biobank. For replication, we externally tested 221 nominally significant associations (p < 0.05) in an independent cohort from FinnGen. To account for potential horizontal pleiotropy and the influence of invalid instrumental variables, we performed sensitivity analyses using MR-Egger regression, weighted median estimator, and MR-PRESSO. Finally, we used multivariable MR controlling for correlated lipid fractions to distinguish the independent effect of plasma TG levels.

    Results: Our results identified 7 disease traits reaching Bonferroni-corrected significance in both the discovery (p < 1.92 × 10-5) and replication analyses (p < 2.26 × 10-4), suggesting a causal relationship between plasma TG levels and ASCVDs, including coronary artery disease (OR 1.33, 95% CI 1.24-1.43, p = 2.47 × 10-13). We also identified 12 disease traits that were Bonferroni-significant in the discovery or replication analysis and at least nominally significant in the other analysis (p < 0.05), identifying plasma TG levels as a novel potential risk factor for 9 non-ASCVD diseases, including uterine leiomyoma (OR 1.19, 95% CI 1.10-1.29, p = 1.17 × 10-5).

    Conclusions: Taking a phenome-wide, two-sample MR approach, we identified causal associations between plasma TG levels and 19 disease traits across organ systems. Our findings suggest unrealized drug repurposing opportunities or adverse effects related to approved and emerging TG-lowering agents, as well as mechanistic insights for future studies.

    Funding: RD is supported by the National Institute of General Medical Sciences of the National Institutes of Health (NIH) (R35-GM124836) and the National Heart, Lung, and Blood Institute of the NIH (R01-HL139865 and R01-HL155915).

    1. Medicine
    Astha Thakkar, Kith Pradhan ... Balazs Halmos
    Research Article

    Background: Cancer patients show increased morbidity with COVID-19 and need effective immunization strategies. Many healthcare regulatory agencies recommend administering 'booster' doses of COVID-19 vaccines beyond the standard 2-dose series, for this group of patients. Therefore, studying the efficacy of these additional vaccine doses against SARS-CoV-2 and variants of concern is of utmost importance in this immunocompromised patient population.

    Methods: We conducted a prospective single arm clinical trial enrolling patients with cancer that had received two doses of mRNA or one dose of AD26.CoV2.S vaccine and administered a 3rd dose of mRNA vaccine. We further enrolled patients that had no or low responses to three mRNA COVID vaccines and assessed the efficacy of a 4th dose of mRNA vaccine. Efficacy was assessed by changes in anti-spike antibody, T-cell activity and neutralization activity were again assessed at baseline and 4 weeks.

    Results: We demonstrate that a 3rd dose of COVID-19 vaccine leads to seroconversion in 57% of patients that were seronegative after primary vaccination series. The immune response is durable as assessed by anti-S antibody titers, T-cell activity and neutralization activity against wild-type SARS-CoV2 and BA1.1.529 at 6 months of follow up. A subset of severely immunocompromised hematologic malignancy patients that were unable to mount an adequate immune response (titer <1000 AU/mL) after the 3rd dose and were treated with a 4th dose in a prospective clinical trial which led to adequate immune-boost in 67% of patients. Low baseline IgM levels and CD19 counts were associated with inadequate seroconversion. Booster doses induced limited neutralization activity against the Omicron variant.

    Conclusions: These results indicate that 3rd dose of COVID vaccine induces durable immunity in cancer patients and an additional dose can further stimulate immunity in a subset of patients with inadequate response.

    Funding: Leukemia lymphoma society, National Cancer Institute.

    Clinical trial identifier: NCT05016622.